About UNITED LAB Company

Federal Pharmaceutical (stock code 03933.HK) was founded in Hong Kong in 1990. It currently has six production entities, including Federal Pharmaceutical Co., Ltd. (Hong Kong), Zhuhai Federal Pharmaceutical Co., Ltd., Zhongshan Branch of Zhuhai Federal Pharmaceutical Co., Ltd., Guangdong Kaiping Jinyi Capsule Co., Ltd., Federal Pharmaceutical (Inner Mongolia) Co., Ltd., and Inner Mongolia Federal Animal Insurance Pharmaceutical Co., Ltd., a professional chemical and biological product R&D center, with products covering pharmaceutical intermediates, APIs and formulations, with a total of more than 14,000 employees. It is a comprehensive company integrating R&D, production and operation Pharmaceutical Group. All of Federal Pharmaceutical's workshops have passed China's new GMP certification, and several products have successively obtained EU GMP certification and US FDA certification. With advanced enzymatic production technology, Federal Pharmaceutical became the first domestic enterprise to obtain the EU CEP certificate for enzymatic amoxicillin, and many other scientific and technological achievements have obtained national patents. Federal Pharmaceutical currently has 11 series of pharmaceutical products with more than 60 varieties, more than 110 varieties, and a total of 5 series of nearly 50 varieties of APIs and intermediates. Among them, Bundeqing received a national invention patent certificate. It is the first domestic imitation product used to treat moderate to severe Alzheimer's dementia. Antibiotic products such as amoxen, tazoxin, ampicin, etc., have been selling well for many years, and their excellent curative effects and quality have been deeply trusted and praised by users. The group continues to promote consistency evaluation work. Currently, several products such as Federal Amoxen capsules (0.25g), Federal cefoxin tablets (0.25g), and bondeqing memantine hydrochloride tablets (10mg) have passed a consistent evaluation of generic drug quality and efficacy, showing that they are consistent with the original research drug in terms of quality and efficacy, and can replace each other clinically with the original research drug. Federal Pharmaceutical has been committed to biopharmaceutical research for more than ten years, and has invested heavily to establish large-scale human insulin and similar production bases in Zhuhai and Zhongshan, thus integrating industry and research in the field of diabetic biopharmaceuticals. Currently on the market are the insulin injection “Yuslin USLIN”, the glycine insulin injection “Federal Yulelin USLEN”, and the Mendon insulin injection Federal Ublin series. The USLIN and UBLIN series products of Yusilong UBLIN use Pichia yeast expression technology and have the advantages of high purity, good safety, and affordability. The glycine insulin injection “Federal Yulelin USLEN” uses advanced purification technology, and the product quality conforms to the standards of the US Pharmacopeia. Federal Pharmaceuticals is the first company in China to have the capacity to produce second-generation and third-generation insulin at the same time. Federal Pharmaceuticals has advanced production equipment and sufficient production capacity. The current annual production capacity is 1.8 billion capsules, 1 billion tablets, 134 million granules, 86 million bags of suspensions, 20 million bottles of oral solution, 117 million bottles of powder, 37.8 million bottles of ointments, 28 million bottles of freeze-dried powder needles, 24 million eye drops, and about 300 million insulin preparations. Federal Pharmaceuticals insists on putting equal emphasis on development and environmental protection, and follows the path of sustainable development. It has successively invested nearly 2 billion yuan in environmental management, introduced advanced international technology and equipment, equipped professional teams, worked hard to build green productivity, and won a series of honorary titles such as “Excellent Innovative Enterprise in Guangdong Province” and “Environmental Social Responsibility Enterprise”. Since 1998, Federal Pharmaceutical has completed more than 30 foreign donation projects in the fields of education, disaster relief, and social welfare, with a donation amount of nearly 100 million yuan. It has organized employees to participate in public welfare activities such as unpaid blood donation, social volunteering, and social charity many times, reflecting its responsibility and mission as a modern enterprise. As always, Federal Pharmaceutical is adhering to the promise of “making life more valuable” and is committed to promoting the development of China's medical and health care industry and providing more high-quality and efficient pharmaceutical products to the community.